Horizon Discovery Group

Activities: Analysis Pharmaceutical

Trending Articles

  1. The new F-Gas Regulation and its impact on pharmaceutical freeze-drying Freeze-drying or lyophilization represents a pivotal process in the life sciences industry. During the past five decades, the technology involved has evolved into a complex,...
  2. Quantoom Biosciences, Univercells and Fiocruz collaborate to advance global RNA vaccine development Together, the companies will develop RNA-based biopharmaceuticals, while also building a dedicated mRNA production facility in Brazil
  3. Gerresheimer begins €100m expansion of its pharmaceutical syringe production capabilities The extension of its Skopje, North Macedonia site will allow Gerresheimer to better serve the pharmaceutical and biotech industries
  4. Ipsen licenses Biomunex Pharmaceuticals' bispecific antibody, BMX-502 The deal makes Biomunex eligible for up to $610m, with Ipsen being responsible for getting the cancer immunotherapy into Phase I clinical trials
  5. Europa Biosite acquires life science product and service supplier, AMSBIO Europa Biosite will now be able to expand its presence across the key US market, while also bolstering its offerings in stem cell research, regenerative medicine and biospecimens

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

Related Content

Research & Development

Cell therapy engages stealth mode to target solid tumours

Cell therapies, such as CAR-T cells, have already generated impressive initial response rates in the clinic for patients suffering from haematological (or blood) cancers, but are yet to make a similar impact in patients with solid tumours, notes Emily M. Anderson, PhD, Principal Scientist, Horizon Discovery
Pharmaceutical

Horizon Discovery expands cell-based CRISPR screening services

Cell line engineering specialist has expanded its range to complement its T cell screening service ­
Manufacturing

Horizon exclusively licenses new base editing technology

Rutgers technology has been incorporated into Horizon Discovery Group’s next-generation gene editing platform
Manufacturing

Horizon Discovery expands CRISPR gene editing portfolio

Gene editing specialist Horizon Discovery has added predesigned synthetic sgRNAs to its offering to streamline CRISPR gene editing workflows
Pharmaceutical

Horizon signs license agreement with Glenmark for CHO cell line

gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line has been licenced to be incorporated into the biomanufacturing process
Manufacturing

Global alliance chooses Horizon Discovery cell line for Zika antibody

Batavia Biosciences, Vanderbilt University Medical Center (VUMC) and IDBiologics will use the cell line expression system to produce and antibody for the potent virus
Recruitment

Horizon Discovery appoints CEO
Subscribe now